Equities analysts expect ABIOMED, Inc. (NASDAQ:ABMD) to announce $0.87 earnings per share for the current quarter, according to Zacks. Five analysts have made estimates for ABIOMED’s earnings, with the highest EPS estimate coming in at $1.25 and the lowest estimate coming in at $0.52. ABIOMED reported earnings per share of $1.03 in the same quarter last year, which indicates a negative year over year growth rate of 15.5%. The business is scheduled to announce its next quarterly earnings results on Thursday, October 29th.
According to Zacks, analysts expect that ABIOMED will report full-year earnings of $4.34 per share for the current financial year, with EPS estimates ranging from $3.85 to $5.34. For the next fiscal year, analysts expect that the company will report earnings of $5.03 per share, with EPS estimates ranging from $4.22 to $6.08. Zacks’ EPS calculations are a mean average based on a survey of research firms that cover ABIOMED.
ABIOMED (NASDAQ:ABMD) last announced its quarterly earnings data on Thursday, August 6th. The medical equipment provider reported $0.58 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.20 by $0.38. ABIOMED had a return on equity of 16.17% and a net margin of 19.88%. The company had revenue of $164.90 million for the quarter, compared to analyst estimates of $144.12 million. During the same quarter in the previous year, the company earned $1.00 EPS. The firm’s revenue for the quarter was down 20.6% compared to the same quarter last year.
A number of brokerages have weighed in on ABMD. BidaskClub lowered ABIOMED from a “buy” rating to a “hold” rating in a report on Tuesday, August 25th. SVB Leerink boosted their price target on ABIOMED from $280.00 to $335.00 and gave the stock a “market perform” rating in a research note on Friday, August 7th. Morgan Stanley boosted their price target on ABIOMED from $152.00 to $217.00 and gave the stock an “underweight” rating in a research note on Friday, August 7th. Finally, OTR Global raised ABIOMED to a “positive” rating in a research note on Monday, July 13th. Two equities research analysts have rated the stock with a sell rating, five have given a hold rating and three have given a buy rating to the stock. The stock currently has a consensus rating of “Hold” and a consensus price target of $221.40.
ABMD traded up $1.54 during trading on Monday, reaching $261.99. The company’s stock had a trading volume of 432,306 shares, compared to its average volume of 338,754. ABIOMED has a 52-week low of $119.01 and a 52-week high of $319.19. The company’s fifty day moving average price is $286.58 and its 200-day moving average price is $235.54. The company has a market capitalization of $11.80 billion, a price-to-earnings ratio of 75.50, a price-to-earnings-growth ratio of 3.30 and a beta of 1.17.
In related news, Director Dorothy E. Puhy sold 7,500 shares of ABIOMED stock in a transaction that occurred on Wednesday, July 15th. The stock was sold at an average price of $275.00, for a total transaction of $2,062,500.00. Following the completion of the transaction, the director now directly owns 7,652 shares in the company, valued at approximately $2,104,300. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Paul Thomas sold 2,000 shares of ABIOMED stock in a transaction that occurred on Monday, August 10th. The stock was sold at an average price of $303.41, for a total value of $606,820.00. Insiders have sold a total of 110,250 shares of company stock worth $33,815,313 in the last three months. Corporate insiders own 3.40% of the company’s stock.
Institutional investors have recently modified their holdings of the stock. Bainco International Investors acquired a new position in shares of ABIOMED during the 1st quarter worth approximately $39,000. Toth Financial Advisory Corp acquired a new position in ABIOMED in the 2nd quarter valued at $43,000. CSat Investment Advisory L.P. raised its holdings in ABIOMED by 17.1% in the 1st quarter. CSat Investment Advisory L.P. now owns 494 shares of the medical equipment provider’s stock valued at $72,000 after acquiring an additional 72 shares during the last quarter. Tower Research Capital LLC TRC raised its holdings in ABIOMED by 331.3% in the 1st quarter. Tower Research Capital LLC TRC now owns 690 shares of the medical equipment provider’s stock valued at $100,000 after acquiring an additional 530 shares during the last quarter. Finally, Cerebellum GP LLC acquired a new position in ABIOMED in the 2nd quarter valued at $127,000. Hedge funds and other institutional investors own 94.94% of the company’s stock.
ABIOMED, Inc engages in the research, development, and sale of medical devices to assist or replace the pumping function of the failing heart. It also provides continuum of care to heart failure patients. The company offers Impella 2.5 catheter, a percutaneous micro heart pump with integrated motor and sensors for use in interventional cardiology; and Impella CP, a device used by interventional cardiologists to support patients in the cath lab and cardiac surgeons in the heart surgery suite.
Recommended Story: History of the Euro STOXX 50 Index
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for ABIOMED Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ABIOMED and related companies with MarketBeat.com's FREE daily email newsletter.